Wednesday, March 04, 2026 9:33:27 AM
Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 after market close and Host Conference Call on March 5 at 8:00 a.m. ET
The Company also expects to receive feedback from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom in the first quarter of 2026.
The Company also expects to receive feedback from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom in the first quarter of 2026.
Recent AQST News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:08:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:04:40 PM
- Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/13/2026 08:01:00 PM
- Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree • GlobeNewswire Inc. • 05/12/2026 01:31:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 09:34:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 09:33:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 09:31:34 PM
- Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims Pattern Of Harm: SueWallSt • PR Newswire (US) • 04/30/2026 01:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/24/2026 09:10:26 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 09:05:43 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 09:00:52 PM
- AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: SueWallSt • PR Newswire (US) • 04/23/2026 01:00:00 PM
- AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm • PR Newswire (US) • 04/21/2026 01:00:00 PM
- AQST Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Aquestive Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm • PR Newswire (US) • 04/14/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:54:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:54:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:53:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:52:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:51:56 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 01:56:19 PM
- AQST Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Aquestive Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm • PR Newswire (US) • 04/07/2026 01:00:00 PM
- AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm • PR Newswire (US) • 03/31/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 11:44:46 AM
- Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
